BioTTT 001
Alternative Names: Ad-TD-nsIL12; BioTTT-001; Recombinant human nsIL12 oncolytic adenovirus injectionLatest Information Update: 08 Jul 2024
At a glance
- Originator Beijing Bio-Targeting Therapeutics Technology
- Developer Beijing Bio-Targeting Therapeutics Technology; Beijing Sanbo Brain Hospital
- Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; Oncolytic viruses; Recombinant proteins
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from the phase I trial in Glioblastoma presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 04 Mar 2024 China Medical University and Beijing Bio-Targeting Therapeutics Technology initiated a phase I trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Monotherapy, Metastatic disease) in April 2024 (Intraperitoneal) (NCT06283134)
- 29 Feb 2024 China Medical University, China in collaboration with Beijing Bio-Targeting Therapeutics Technology plans a phase II trial for Gastric cancer (Metastatic disease, Combination therapy, Monotherapy) (Intraperitoneal, infusion) in April 2024 (NCT06283121)